Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives - Episode 6
Optimal Strategies for Navigating Referral and Bridging Therapy for CAR T-Cell Therapy in R/R DLBCL Patients
Experts discuss when a patient should be referred from community practice to an academic or specialized program, the factors influencing the choice and timing of bridging therapy before CAR T infusion, and how bridging therapy is coordinated between academic and community settings.
Video content above is prompted by the following:
- At what point should a patient be referred from community practice to an academic or specialized program?
- What factors influence your choice and the timing of bridging therapy relative to planned CAR T infusion?
- How do you coordinate bridging therapy, and is it typically done in the academic or community setting in your clinical practice?
Related Content:
